Abstract
Background: In an era of endemic SARS-CoV-2 transmission, countries are continuing to evaluate how best to schedule ongoing COVID-19 booster vaccinations. Mathematical modelling provides a useful tool to predict the benefit of future vaccination strategies, incorporating the loss of protection due to waning immunity and strain mutation. Methods: We adapted a combined immunological-population transmission model for SARS-CoV-2, to better capture contemporary understanding of exposure- and vaccine-derived immunity, to simulate ongoing endemic transmission of SARS-CoV-2 in a highly exposed high-income setting. We used this model to estimate the impact of targeted booster dose strategies in the older population, both in the context of continued circulation of the current dominant viral strain, and in the presence of a new antigenically distinct variant. Results: We found that at the population level, an annual COVID-19 vaccine booster dose to the 65+ years population at 60% coverage could avert 10-17% of hospitalisations over a single wave, depending on how well-matched the vaccine is to the circulating SARS-CoV-2 strain. With lower coverage of 40%, estimated impact was between 9-12%. A second booster dose to the 75+ population after 6 months was particularly beneficial if a new distinct variant strain increases the magnitude of the wave. Conclusions: This adapted model captures endemic viral transmission and could readily be used to explore vaccine impact across other settings.
Competing Interest Statement
ABH has previously received funding from the World Health Organization (both paid to the institution and individually) for work relating to modelling pandemic-era COVID-19 vaccine impact. BL declares grants paid to their institution from the Australian National Health and Medical Research Council and Medical Research Future Fund.
Funding Statement
ABH and DJM are supported by a National Health and Medical Research Council (NHMRC) Investigator Grants (APP2009278, APP1194109). The contents of the published material are solely the responsibility of the Administering Institution, Participating Institutions, or individual authors and do not reflect the views of the NHMRC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos